绝经前女性药物性骨丢失可接受吗?一项实用性骨折风险建模研究
该研究基于FRAX®工具联合骨密度和骨小梁评分调整,模拟绝经前女性不同程度药物性骨丢失对晚年10年主要骨质疏松性骨折风险的影响。结果显示可耐受的骨丢失程度主要取决于基线骨状态,峰值骨量在50百分位及以上者可耐受骨密度和骨小梁评分各降低10%而不达到治疗阈值,而第5百分位者无药物性丢失也将在75岁前达到治疗阈值。作者建议个体化评估药物性绝经前骨丢失的风险获益。
要点
- 可耐受的骨丢失程度主要取决于基线骨状态,而非固定阈值
- 峰值骨密度和骨小梁评分在第50百分位及以上者可耐受各降低10%而不达治疗阈值
- 峰值骨量在第5百分位者即使无药物性骨丢失也将在75岁前达到治疗阈值
核心结论
- 对于评估药物性绝经前骨丢失的后果,作者提出个体化方法,同时考虑骨密度和骨小梁评分的丢失、基线骨状态以及基于骨丢失不可逆假设的晚年骨折风险影响。
研究设计与样本
- 研究为系统性骨折风险建模练习,使用FRAX®工具联合骨密度和骨小梁评分调整,模拟绝经前药物性骨密度和骨小梁评分丢失对晚年10年主要骨质疏松性骨折风险的影响,并将结果与美国和英国治疗指南对照。
主要发现
- 峰值骨量在第5至第50百分位之间的女性,不同程度的骨密度和骨小梁评分丢失可被耐受而不达到治疗阈值。
- 峰值骨密度和骨小梁评分在第50百分位或以上者可耐受骨密度和骨小梁评分各降低10%而不在75岁前达到治疗阈值。
- 峰值骨量在第5百分位者即使无药物性骨密度或骨小梁评分降低,也将在75岁前达到治疗阈值。
- 峰值骨量在第25百分位者可耐受骨密度降低4%和骨小梁评分下降2%而不在75岁前达到治疗阈值。
关键数值与推荐
- 可耐受骨丢失程度以美国或英国治疗指南启动治疗的阈值为判定标准。
- 峰值骨密度和骨小梁评分在第50百分位或以上者可耐受各降低10%而不在75岁前达到治疗阈值。
- 峰值骨量在第25百分位者可耐受骨密度降低4%和骨小梁评分下降2%而不在75岁前达到治疗阈值。
- 峰值骨量在第5百分位者无药物性骨密度或骨小梁评分降低也将在75岁前达到治疗阈值。
临床怎么用
- 作者建议对导致绝经前骨丢失的药物进行风险获益评估时应个体化,考虑基线状态以及后续骨密度和骨小梁评分丢失。
- 作者提出个体化方法同时考虑骨密度和骨小梁评分的丢失、基线骨状态以及基于骨丢失不可逆假设的晚年骨折风险影响,供临床医生和监管机构评估药物性绝经前骨丢失的后果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Premenopausal bone loss increases fracture risk later in life. Depending on peak values, varying degrees of bone mass and microarchitectural loss can be tolerated. We suggest that risk-benefit assessments of drugs that cause premenopausal bone loss be individualized considering baseline status and subsequent BMD and TBS loss. INTRODUCTION: It is logical that drug-induced loss of bone mass and microarchitecture in young adults increase fracture risk later in life. However, no existing data quantify how drug-induced bone loss in younger adults impacts fracture risk later in life. As such, no guidance exists to address the question "How much, if any, drug-induced bone loss in premenopausal women is acceptable?" Thus, we performed a systematic fracture risk modeling exercise examining various degrees of bone loss, and estimated the impact on 10-year major osteoporosis-related fracture risk later in life. METHODS: The FRAX® tool was used in conjunction with BMD and trabecular bone score (TBS) adjustment to estimate major osteoporotic fracture probability later in life resulting from varying degrees of hypothetical premenopausal drug-induced BMD and TBS loss. The resulting 10-year fracture probabilities were assessed against the US and the UK treatment guidance to determine the amount of premenopausal BMD and TBS loss that would result in a recommendation to initiate medical treatment to reduce fracture risk later in life that would not otherwise have been recommended in the absence of premenopausal bone loss. RESULTS: For women whose peak bone mass is between the 5th and 50th percentiles, varying degrees of BMD and TBS loss could be tolerated without reaching treatment thresholds. The degree of tolerable bone loss was primarily dependent on baseline bone status. Those whose peak BMD and TBS are in the 50th percentile or above could tolerate a 10% reduction in BMD and TBS without reaching treatment thresholds by age 75, whereas those in the 5th percentile would reach treatment thresholds by age 75 with no drug-induced reduction in BMD or TBS. Women in the 25th percentile could tolerate a 4% BMD loss and 2% TBS decline without reaching treatment thresholds by age 75. CONCLUSIONS: For clinicians and regulatory bodies to assess the consequence of drug-induced premenopausal bone loss, we propose an individualized approach considering both loss of BMD and TBS in concert with baseline bone status and the resultant effect on fracture risk in later life using the assumption that such losses are irreversible.
引用
- Binkley N, Besuyen R, Fuerst T, et al. Is drug-induced bone loss acceptable in premenopausal women? A practical fracture risk modeling exercise. Osteoporos Int. 2017. PMID: 29018923. doi:10.1007/s00198-017-4258-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。